United States News All stories

Amgen (NASDAQ:AMGN) received U.S. FDA approval to update the prescribing information for IMDELLTRA, reducing the initial monitoring time to 6–8 hours.

Boeing (NYSE:BA) and American Airlines (NASDAQ:AAL) completed the first 737 MAX landing gear exchange on September 14, 2026.

Canaan (NASDAQ:CAN) released its August 2026 update, mining 44 Bitcoin and securing US$13.9 million from asset sales.

Pasithea Therapeutics (NASDAQ:KTTA) announced that it will present initial clinical data from Part A of its ongoing Phase 1/1b trial evaluating PAS-004 in adults with neurofibromatosis type 1 (NF1).

RF Industries (NASDAQ:RFIL) reported record third-quarter fiscal 2026 net sales of $23.96 million, representing a 21% year-over-year increase.

Corbus Pharmaceuticals (NASDAQ:CRBP) reported Phase 1b data showing a 5% mean weight loss with CRB-913 after 12 weeks.

Definium Therapeutics (NASDAQ:DFTX) reported positive topline results from the Phase 3 Panorama study evaluating DT120 (lysergide) Orally Disintegrating Tablet in adults with generalized anxiety disorder.

Phio Pharmaceuticals (NASDAQ:PHIO) submitted a meeting request and comprehensive briefing package to the U.S. Food and Drug Administration to support the next phase of development for its INTASYL siRNA candidate PH-762.

Telix (NASDAQ:TLX) received U.S. Food and Drug Administration approval for Pixclara, or floretyrosine F 18, as a PET imaging drug for evaluating glioma.

Hub Group (NASDAQ:HUBG) released preliminary unaudited first-half 2026 results, warning investors that the company expects to report an operating loss before one-time charges due to increased operating pressures and accounting-related expenses.

Surf Air Mobility (NYSE:SRFM) said subsidiary Mokulele Airlines secured a four-year U.S. Department of Transportation Essential Air Service contract valued at $19.4 million to continue serving Lanaʻi, Hawaiʻi.

Coda Octopus Group (NASDAQ:CODA) reported fiscal third-quarter 2026 revenue of $7.7 million for the period ended July 31, 2026, representing a 9.2% increase compared with the same period last year.

Brookfield Asset Management (NYSE:BAM) and American Real Estate Partners (AREP) announced that affiliates of Brookfield have agreed to acquire a minority interest in AREP.

Hain Celestial (NASDAQ:HAIN) reported fiscal fourth-quarter and full-year 2026 results showing improved cash generation and lower leverage despite declining sales.

Hain Celestial (NASDAQ:HAIN) agreed to sell the majority of its International business to private equity firm AURELIUS for approximately $323 million in cash as part of its strategic transformation plan.

Radiopharm Theranostics (NASDAQ:RADX) reported that RAD101 PET achieved 93% concordance with MRI across all evaluable lesions in an interim Phase 2b analysis, meeting the imaging trial’s primary endpoint.

Perspective Therapeutics entered a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate targeted alpha therapy PSV359 in combination with Keytruda in FAP-α-positive solid tumors.

WisdomTree (NYSE:WT) reported record assets under management of approximately $174 billion globally at the end of August 2026, supported by strong client demand and continued inflows across its investment products.

The Elmet Group (NASDAQ:ELMT) plans to deploy a committed $450 million U.S. Department of War investment to develop a more vertically integrated tungsten supply chain.

Digital Realty (NYSE:DLR) formed a strategic joint venture with Rönesans Infrastructure to develop and operate next-generation, carrier-neutral data centers across Türkiye.

Brent crude for October and November delivery rose more than 3% above $108 a barrel Monday, while U.S. benchmark WTI gained 2.3% to around $102.

BioNTech (NASDAQ:BNTX) and OncoC4 reported updated Phase 3 PRESERVE-003 data showing median overall survival of 18.5 months with gotistobart versus 10.0 months with docetaxel in previously treated squamous NSCLC.

Cullinan Therapeutics (NASDAQ:CGEM), Taiho Oncology, and Taiho Pharmaceutical reported that zipalertinib plus chemotherapy improved median progression-free survival by six months versus chemotherapy alone in the Phase 3 REZILIENT3 trial.

Whitehawk Therapeutics (NASDAQ:WHWK) reported WCLC 2026 real-world analyses supporting protein tyrosine kinase 7, or PTK7, as a potential antibody-drug conjugate target in pretreated EGFR wild-type non-small cell lung cancer.